Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Ledipasvir/sofosbuvir – nutzenbewertung gemäß § 35a SGB V. [Ledipasvir/sofosbuvir - benefit assessment according to §35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 282. 2015 Indexing Status Subject indexing assigned by CRD MeSH Hepatitis C, Chronic; Humans; Outcome Assessment (Health Care) Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32015001063 Date abstract record published 21/10/2015 |